Natera Seeks Japan Approval for Signatera in Bladder Cancer
NTRA has more than doubled off its 52-week low of $133.01.
Summary
Natera has submitted Signatera to Japan's PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. This follows the June PMDA approval for colorectal cancer, marking the second indication in Japan. The submission is backed by Phase 3 IMvigor011 data and builds on recent U.S. FDA approval and NCCN guideline inclusion for the same test in MIBC. Bladder cancer affects over 34,000 people annually in Japan, with MIBC representing a more aggressive subset. Approval would expand Natera's oncology footprint in a key market and strengthen Signatera's global regulatory profile.
At the time of this announcement, NTRA was trading at $270.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.4B. The 52-week trading range was $133.01 to $288.04. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.